Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives

World Journal of Hepatology

Volumn 7, Issue 9, 2015, Pages 1168-1183

  Slotta, Jan Erik ^a   Kollmar, Otto ^a   Ellenrieder, Volker ^a   Ghadimi, B Michael ^a   Homayounfar, Kia ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Extended indications; Hepatocellular carcinoma; Interventional therapy; Multimodal treatment; Surgical therapy

Indexed keywords

EID: 84929791514     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i9.1168     Document Type: Review

References (162)

1. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084 [PMID: 14642630]
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47 Suppl: S2-S6 [PMID: 23632345 DOI: 10.1097/MCG.0b013e3182872f29]
3. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med 2012; 4: 19-37 [PMID: 24367230 DOI: 10.2147/HMER.S16316]
4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available from: URL: http://www.seer.cancer.gov/faststats
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
6. Simonetti RG, Cammà C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972 [PMID: 1649041]
7. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124]
8. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044 [PMID: 16404738]
9. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101]
10. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331 [PMID: 11836196]
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051]
12. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
13. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56: e1-48 [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124]
14. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409 [PMID: 6201411]
15. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575 [PMID: 11394657]
16. Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v59-v64 [PMID: 20555104 DOI: 10.1093/annonc/mdq166]
17. Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012; 2012: 859076 [PMID: 22655201 DOI: 10.1155/2012/859076]
18. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338 [PMID: 10518312]
19. Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012; 4: 256-261 [PMID: 23060970 DOI: 10.4254/wjh.v4.i9.256]
20. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428]
21. Eun HS, Kim MJ, Kim HJ, Ko KH, Moon HS, Lee ES, Kim SH, Lee HY, Lee BS. The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. Korean J Hepatol 2011; 17: 189-198 [PMID: 22102385 DOI: 10.3350/kjhep.2011.17.3.189]
22. Davila JA, Duan Z, McGlynn KA, El-Serag HB. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol 2012; 46: 71-77 [PMID: 22157221 DOI: 10.1097/MCG.0b013e318224d669]
23. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, Tang A, Lee JJ, Mok TS, Lai PB, Johnson PJ, Zee B. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006; 17: 1083-1089 [PMID: 16600982]
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
25. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009; 14: 95-100 [PMID: 19144678 DOI: 10.1634/theoncologist.2008-0185]
26. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76 [PMID: 19144684 DOI: 10.1634/theoncologist.2008-0191]
27. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014; 68: 609-617 [PMID: 24283303 DOI: 10.1111/ijcp.12352]
28. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol) 2014; 26: 488-496 [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031]
29. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32: 1028-1035 [PMID: 24748335 DOI: 10.1007/s10637-014-0100-y]
30. Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. Liver Cancer 2014; 3: 125-131 [PMID: 24945003 DOI: 10.1159/000343868]
31. Liccioni A, Reig M, Bruix J. FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive? J Hepatol 2014; 61: 164-165 [PMID: 24681343 DOI: 10.1016/j.jhep.2014.03.024]
32. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RTP, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre MA, Meinhardt G, Llovet JM. Oral Abstract Session, Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol 2014; 32: 5s
33. Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013; 27: 351-363 [PMID: 23781519]
34. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2013; 8: e61361 [PMID: 24069133 DOI: 10.1371/journal.pone.0061361]
35. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013; 12: CD003046 [PMID: 24357457 DOI: 10.1002/14651858.CD003046.pub3]
36. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013; 8: e80276 [PMID: 24244668 DOI: 10.1371/journal.pone.0080276]
37. Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014; 9: e84484 [PMID: 24404166 DOI: 10.1371/journal. pone.0084484]
38. Ni JY, Xu LF, Sun HL, Zhou JX, Chen YT, Luo JH. Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients. J Cancer Res Clin Oncol 2013; 139: 2021-2033 [PMID: 24072235]
39. Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J Cancer Res Clin Oncol 2015; 141: 1-9 [PMID: 24889505]
40. Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20: 5987-5998 [PMID: 24876721 DOI: 10.3748/wjg.v20.i20.5987]
41. Huang G, Chen X, Lau WY, Shen F, Wang RY, Yuan SX, Geng WX, Zhou WP. Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. Br J Surg 2014; 101: 1006-1015 [PMID: 24863168 DOI: 10.1002/bjs.9539]
42. Eichler K, Zangos S, Gruber-Rouh T, Vogl TJ, Mack MG. Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period. J Clin Gastroenterol 2012; 46: 796-801 [PMID: 22955262 DOI: 10.1097/MCG.0b013e3182641806]
43. Awad T, Thorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database Syst Rev 2009; (4): CD007611 [PMID: 19821432 DOI: 10.1002/14651858.CD007611.pub2]
44. Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Wang H, Gao X, Chang X, An L, Chen Y, Yang Y. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases. Front Med 2015; 9: 63-71 [PMID: 25001101]
45. Chen HW, Lai EC, Zhen ZJ, Cui WZ, Liao S, Lau WY. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg 2011; 9: 188-191 [PMID: 21093616 DOI: 10.1016/j.ijsu.2010.11.008]
46. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]
47. Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol 2013; 25: 620-627 [PMID: 23325276 DOI: 10.1097/MEG.0b013e32835c ed13]
48. Schuld J, Richter S, Kollmar O. The role of cryosurgery in the treatment of colorectal liver metastases: a matched-pair analysis of cryotherapy vs. liver resection. Hepatogastroenterology 2014; 61: 192-196 [PMID: 24895819]
49. Sheen AJ, Siriwardena AK. The end of cryotherapy for the treatment of nonresectable hepatic tumors? Ann Surg Oncol 2005; 12: 202-204 [PMID: 15827810]
50. Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015; 45: 59-74 [PMID: 24965914 DOI: 10.1111/hepr.12378]
51. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451 [PMID: 12563138]
52. Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLoS One 2013; 8: e76119 [PMID: 24146824 DOI: 10.1371/journal.pone.0076119]
53. Carrafiello G, Laganà D, Ianniello A, Dionigi G, Novario R, Recaldini C, Mangini M, Cuffari S, Fugazzola C. Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australas Radiol 2007; 51: 550-554 [PMID: 17958690]
54. Andreano A, Galimberti S, Franza E, Knavel EM, Sironi S, Lee FT, Meloni MF. Percutaneous microwave ablation of hepatic tumors: prospective evaluation of postablation syndrome and postprocedural pain. J Vasc Interv Radiol 2014; 25: 97-105.e1-2 [PMID: 24286938 DOI: 10.1016/j.jvir.2013.09.005]
55. Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D, Martinie JB, Iannitti DA, Bloomston M, Schmidt C, Khabiri H, Shirley LA, Martin RC, Tsai S, Turaga KK, Christians KK, Rilling WS, Gamblin TC. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259: 1195-1200 [PMID: 24096760 DOI: 10.1097/SLA.0000000000000234]
56. Zhang XG, Zhang ZL, Hu SY, Wang YL. Ultrasound-guided ablative therapy for hepatic malignancies: a comparison of the therapeutic effects of microwave and radiofrequency ablation. Acta Chir Belg 2014; 114: 40-45 [PMID: 24720137]
57. Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc 2014; 28: 3429-3434 [PMID: 24935203]
58. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25 [PMID: 17103105]
59. Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013; 163: 123-127 [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x]
60. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; (3): CD004787 [PMID: 21412886 DOI: 10.1002/14651858. CD004787.pub2]
61. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012; 56: 984-986 [PMID: 22008737 DOI: 10.1016/j.jhep.2011.08.017]
62. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862]
63. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 [PMID: 11981766]
64. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54 [PMID: 12091661]
65. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 [PMID: 12540794]
66. Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015; 17: 52-65 [PMID: 24961288 DOI: 10.1111/hpb.12273]
67. Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for HCC. Ann Surg Oncol 2008; 15: 993-1000 [PMID: 18236111 DOI: 10.1245/s10434-007-9787-8]
68. Seehofer D, Nebrig M, Denecke T, Kroencke T, Weichert W, Stockmann M, Somasundaram R, Schott E, Puhl G, Neuhaus P. Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 2012; 26: 764-774 [PMID: 22432589 DOI: 10.1111/j.1399-0012.2012.01609.x]
69. Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE, Nalesnik M, Geller DA, Steel JL, Gamblin TC. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008; 15: 3169-3177 [PMID: 18696158 DOI: 10.1245/s10434-008-0071-3]
70. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267 [PMID: 16826556]
71. Sotiropoulos GC, Malagó M, Molmenti E, Paul A, Nadalin S, Brokalaki EI, Verhagen R, Dirsch O, Gerken G, Lang H, Broelsch CE. Efficacy of transarterial chemoembolization prior to liver transplantation for hepatocellular carcinoma as found in pathology. Hepatogastroenterology 2005; 52: 329-332 [PMID: 15816428]
72. Sotiropoulos GC, Malago M, Molmenti EP, Radtke A, Brokalaki EI, Nadalin S, Lang H, Frilling A, Baba HA, Kühl H, Verhagen R, Broelsch CE. Disease course after liver transplantation for hepatocellular carcinoma in patients with complete tumor necrosis in liver explants after performance of bridging treatments. Eur J Med Res 2005; 10: 539-542 [PMID: 16356871]
73. Thorat A, Lee CF, Wu TH, Chan KM, Chou HS, Lee WC. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: a centre experience. Hepatogastroenterology 2013; 60: 2076-2079 [PMID: 24719950]
74. Zhou Y, Zhang X, Wu L, Ye F, Su X, Shi L, Li B. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol 2013; 13: 51 [PMID: 23509884 DOI: 10.1186/1471-230X-13-51]
75. Cheng X, Sun P, Hu QG, Song ZF, Xiong J, Zheng QC. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. J Cancer Res Clin Oncol 2014; 140: 1159-1170 [PMID: 24752339]
76. Murthy R, Habbu A, Salem R. Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. Biomed Imaging Interv J 2006; 2: e43 [PMID: 21614250 DOI: 10.2349/biij.2.3.e43]
77. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56: 464-473 [PMID: 21816126 DOI: 10.1016/j.jhep.2011.07.012]
78. Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int 2015; 35: 1036-1047 [PMID: 24750853 DOI: 10.1111/liv.12574]
79. Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology 2013; 84 Suppl 1: 34-39 [PMID: 23428856 DOI: 10.1159/000345887]
80. Marin HL, Furth EE, Olthoff K, Shaked A, Soulen MC. Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma. J Gastrointestin Liver Dis 2009; 18: 169-176 [PMID: 19565046]
81. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys 2011; 81: 460-467 [PMID: 20888138 DOI: 10.1016/j.ijrobp.2010.06.010]
82. El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015; 35: 627-635 [PMID: 25040497 DOI: 10.1111/liv.12637]
83. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664 [PMID: 18172187]
84. Jihye C, Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer 2012; 1: 216-225 [PMID: 24159586 DOI: 10.1159/000343836]
85. Kim SW, Oh D, Park HC, Lim do H, Shin SW, Cho SK, Gwak GY, Choi MS, Paik YH, Paik SW. Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat Oncol J 2014; 32: 14-22 [PMID: 24724047 DOI: 10.3857/roj.2014.32.1.14]
86. Chen WJ, Yuan SF, Zhu LJ, Sun XN, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. J BUON 2014; 19: 692-697 [PMID: 25261654]
87. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014; 88: 1041-1047 [PMID: 24661657 DOI: 10.1016/j.ijrobp.2014.01.017]
88. Lin ZZ, Chou CH, Cheng AL, Liu WL, Chia-Hsien Cheng J. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. Int J Cancer 2014; 135: 492-501 [PMID: 24375034 DOI: 10.1002/ijc.28682]
89. Truant S, Oberlin O, Sergent G, Lebuffe G, Gambiez L, Ernst O, Pruvot FR. Remnant liver volume to body weight ratio > or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg 2007; 204: 22-33 [PMID: 17189109]
90. Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg 2009; 33: 797-803 [PMID: 19172348 DOI: 10.1007/s00268-008-9878-0]
91. Yaprak O, Guler N, Altaca G, Dayangac M, Demirbas T, Akyildiz M, Ulusoy L, Tokat Y, Yuzer Y. Ratio of remnant to total liver volume or remnant to body weight: which one is more predictive on donor outcomes? HPB (Oxford) 2012; 14: 476-482 [PMID: 22672550 DOI: 10.1111/j.1477-2574.2012.00483.x]
92. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg 2012; 29: 6-17 [PMID: 22441614 DOI: 10.1159/000335713]
93. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280 [PMID: 16955381]
94. Lin XJ, Yang J, Chen XB, Zhang M, Xu MQ. The critical value of remnant liver volume-to-body weight ratio to estimate posthepatectomy liver failure in cirrhotic patients. J Surg Res 2014; 188: 489-495 [PMID: 24569034 DOI: 10.1016/j.jss.2014.01.023]
95. Nanashima A, Tobinaga S, Kunizaki M, Miuma S, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Strategy of treatment for hepatocellular carcinomas with vascular infiltration in patients undergoing hepatectomy. J Surg Oncol 2010; 101: 557-563 [PMID: 20213729 DOI: 10.1002/jso.21534]
96. Zhou YM, Sui CJ, Li B, Xu F, Kan T, Yang JM. Results of en bloc resection for hepatocellular carcinoma extending to adjacent organs. Can J Surg 2012; 55: 222-226 [PMID: 22617536 DOI: 10.1503/cjs.028410]
97. Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg 2010; 34: 1028-1033 [PMID: 20174806 DOI: 10.1007/s00268-010-0400-0]
98. Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012; 18: 6398-6408 [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398]
99. Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carcinoma. Surg Today 2009; 39: 833-843 [PMID: 19784720 DOI: 10.1007/s00595-008-4024-z]
100. Zhou Y, Xu D, Wu L, Li B. Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Langenbecks Arch Surg 2011; 396: 1109-1117 [PMID: 21476060 DOI: 10.1007/s00423-011-0784-9]
101. Chen J, Huang K, Wu J, Zhu H, Shi Y, Wang Y, Zhao G. Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2011; 56: 1626-1633 [PMID: 21082347 DOI: 10.1007/s10620-010-1482-0]
102. Ye JZ, Miao ZG, Wu FX, Zhao YN, Ye HH, Li LQ. Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 1771-1777 [PMID: 22901120]
103. Tang YH, Wen TF, Chen X. Anatomic versus non-anatomic liver resection for hepatocellular carcinoma: a systematic review. Hepatogastroenterology 2013; 60: 2019-2025 [PMID: 24719944]
104. Gagner M, Rheault M, Dubuc J. Laparoscopic partial hepatectomy for liver tumor (abstract). Surg Endosc 1992; 6: 99
105. Takahashi M, Wakabayashi G, Nitta H, Takeda D, Hasegawa Y, Takahara T, Ito N. Pure laparoscopic right hepatectomy by anterior approach with hanging maneuver for large intrahepatic cholangiocarcinoma. Surg Endosc 2013; 27: 4732-4733 [PMID: 24170066 DOI: 10.1007/s00464-013-3202-2]
106. Yoon YS, Han HS, Cho JY, Ahn KS. Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver. Surg Endosc 2010; 24: 1630-1637 [PMID: 20035349 DOI: 10.1007/s00464-009-0823-6]
107. Lee W, Han HS, Yoon YS, Cho JY, Choi Y, Shin HK. Role of intercostal trocars on laparoscopic liver resection for tumors in segments 7 and 8. J Hepatobiliary Pancreat Sci 2014; 21: E65-E68 [PMID: 24841194 DOI: 10.1002/jhbp.123]
108. Twaij A, Pucher PH, Sodergren MH, Gall T, Darzi A, Jiao LR. Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis. World J Gastroenterol 2014; 20: 8274-8281 [PMID: 25009403 DOI: 10.3748/wjg.v20.i25.8274]
109. Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, Sutton R, Liu XB, Hu WM. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. World J Gastroenterol 2012; 18: 6657-6668 [PMID: 23236242 DOI: 10.3748/wjg.v18. i45.6657]
110. Herman P, Coelho FF. Laparoscopic resection for hepatocellular carcinoma: eastern and western experiences. Chin J Cancer Res 2014; 26: 234-236 [PMID: 25035647 DOI: 10.3978/j.issn.1000-9604.2014.06.19]
111. Kim HJ, Kim MK. Laparoscopic resection for hepatocellular carcinoma: comparison between Middle Eastern and Western experience. Chin J Cancer Res 2014; 26: 245-246 [PMID: 25035650 DOI: 10.3978/j.issn.1000-9604.2014.06.20]
112. Lin NC, Nitta H, Wakabayashi G. Laparoscopic major hepatectomy: a systematic literature review and comparison of 3 techniques. Ann Surg 2013; 257: 205-213 [PMID: 23263192 DOI: 10.1097/SLA.0b013e31827da7fe]
113. Vigano L, Laurent A, Tayar C, Tomatis M, Ponti A, Cherqui D. The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg 2009; 250: 772-782 [PMID: 19801926 DOI: 10.1097/SLA.0b013e3181bd93b2]
114. Dagher I, O'Rourke N, Geller DA, Cherqui D, Belli G, Gamblin TC, Lainas P, Laurent A, Nguyen KT, Marvin MR, Thomas M, Ravindra K, Fielding G, Franco D, Buell JF. Laparoscopic major hepatectomy: an evolution in standard of care. Ann Surg 2009; 250: 856-860 [PMID: 19806057 DOI: 10.1097/SLA.0b013e3181bcaf46]
115. Kluger MD, Vigano L, Barroso R, Cherqui D. The learning curve in laparoscopic major liver resection. J Hepatobiliary Pancreat Sci 2013; 20: 131-136 [PMID: 23064988 DOI: 10.1007/s00534-012-0571-1]
116. Chan FK, Cheng KC, Yeung YP. Laparoscopic liver resection: lessons learnt after 100 cases. Hong Kong Med J 2014; 20: 386-392 [PMID: 24722724 DOI: 10.12809/hkmj134066]
117. Lai EC, Yang GP, Tang CN. Robot-assisted laparoscopic liver resection for hepatocellular carcinoma: short-term outcome. Am J Surg 2013; 205: 697-702 [PMID: 23561638 DOI: 10.1016/j.amjsurg.2012.08.015]
118. Pelletier JS, Gill RS, Shi X, Birch DW, Karmali S. Robotic-assisted hepatic resection: a systematic review. Int J Med Robot 2013; 9: 262-267 [PMID: 23749316 DOI: 10.1002/rcs.1500]
119. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-676 [PMID: 14100514]
120. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, Blanchard H, Martin AJ, Porter KA. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168: 392-415 [PMID: 4877589]
121. Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-278 [PMID: 18306328 DOI: 10.1002/lt.21368]
122. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17 Suppl 2: S44-S57 [PMID: 21695773 DOI: 10.1002/lt.22365]
123. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528]
124. Lai Q, Nudo F, Mennini G, Spoletini G, Morabito V, Levi SG, Melandro F, Guglielmo N, Berloco PB, Rossi M. Expanded criteria for hepatocellular carcinoma after liver transplantation: a 20-year evolution. Hepatogastroenterology 2013; 60: 2039-2041 [PMID: 24719947]
125. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]
126. Chan SC, Fan ST. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. Hepatobiliary Surg Nutr 2013; 2: 84-88 [PMID: 24570921 DOI: 10.3978/j.issn.2304-3881.2012.12.04]
127. Pichlmayr R, Ringe B, Gubernatis G, Hauss J, Bunzendahl H. [Transplantation of a donor liver to 2 recipients (splitting transplantation)--a new method in the further development of segmental liver transplantation]. Langenbecks Arch Chir 1988; 373: 127-130 [PMID: 3287073]
128. Broelsch CE, Emond JC, Whitington PF, Thistlethwaite JR, Baker AL, Lichtor JL. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg 1990; 212: 368-375; discussion 375-377 [PMID: 2396888]
129. Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet 1989; 2: 497 [PMID: 2570198]
130. Strong R, Ong TH, Pillay P, Wall D, Balderson G, Lynch S. A new method of segmental orthotopic liver transplantation in children. Surgery 1988; 104: 104-107 [PMID: 3291166]
131. Rupertus K, Kollmar O, Scheuer C, Junker B, Menger MD, Schilling MK. Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clin Exp Metastasis 2007; 24: 39-48 [PMID: 17260102]
132. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant 2014; 19: 253-260
133. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010; 30: 1247-1258 [PMID: 20602682 DOI: 10.1111/j.1478-3231.2010.02303. x]
134. Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 1226-1236
135. Taefi A, Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database Syst Rev 2013; 6: CD006935 [PMID: 23813393 DOI: 10.1002/14651858. CD006935.pub2]
136. Zheng Z, Liang W, Milgrom DP, Zheng Z, Schroder PM, Kong NS, Yang C, Guo Z, He X. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation 2014; 97: 227-234 [PMID: 24142034 DOI: 10.1097/TP.0b013e3182a89383]
137. Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford) 2012; 14: 635-645 [PMID: 22882201 DOI: 10.1111/j.1477-2574.2012.00500.x]
138. Rahman A, Assifi MM, Pedroso FE, Maley WR, Sola JE, Lavu H, Winter JM, Yeo CJ, Koniaris LG. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg 2012; 16: 1897-1909 [PMID: 22836922]
139. Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, Martinie JB, Russo MW, Iannitti DA. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014; 16: 1102-1109 [PMID: 24964271 DOI: 10.1111/hpb.12300]
140. Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol 2012; 10: 163 [PMID: 22897815 DOI: 10.1186/1477-7819-10-163]
141. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014; 61: 82-88 [PMID: 24650695 DOI: 10.1016/j.jhep.2014.03.012]
142. Liu PH, Lee YH, Hsu CY, Hsia CY, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status. J Gastrointest Surg 2014; 18: 1623-1631 [PMID: 24871082 DOI: 10.1007/s11605-014-2546-9]
143. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013; 8: e68193 [PMID: 23874536 DOI: 10.1371/journal.pone.0068193]
144. Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol 2014; 20: 3087-3099 [PMID: 24696596 DOI: 10.3748/wjg.v20.i12.3087]
145. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013; 108: 21-24 [PMID: 23287988 DOI: 10.1038/bjc.2012.556]
146. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI: 10.1016/S1470-2045(12)70490-4]
147. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol 2014; 20: 7525-7533 [PMID: 24976693 DOI: 10.3748/wjg.v20.i24.7525]
148. Ishizawa T, Mise Y, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J Hepatobiliary Pancreat Sci 2010; 17: 389-393 [PMID: 19924372 DOI: 10.1007/s00534-009-0231-2]
149. Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Liver Int 2013; 33: 1594-1600 [PMID: 23654354 DOI: 10.1111/liv.12199]
150. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009; 250: 922-928 [PMID: 19855258 DOI: 10.1097/SLA.0b013e3181b977a5]
151. Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol 2012; 27: 51-58 [PMID: 22004366 DOI: 10.1111/j.1440-1746.2011.06947.x]
152. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010; 10: 78 [PMID: 20618937 DOI: 10.1186/1471-230X-10-78]
153. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, Pinna AD. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307 [PMID: 23603669 DOI: 10.1016/j.jhep.2013.04.009]
154. Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, Sheu JC, Chen CH. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009; 16: 848-855 [PMID: 19159983 DOI: 10.1245/s10434-008-0282-7]
155. Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology 2011; 259: 286-295 [PMID: 21330557 DOI: 10.1148/radiol.10101072]
156. Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg 2009; 13: 1313-1320 [PMID: 19418103 DOI: 10.1007/s11605-009-0903-x]
157. Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg 2009; 13: 1921-1928 [PMID: 19727969 DOI: 10.1007/s11605-009-0998-0]
158. Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg 2014; 38: 490-496 [PMID: 24132826 DOI: 10.1007/s00268-013-2290-4]
159. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011; 81 Suppl 1: 158-164 [PMID: 22212951 DOI: 10.1159/000333280]
160. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol 2009; 40: 834-842 [PMID: 19200581 DOI: 10.1016/j.humpath.2008.11.005]
161. Homayounfar K, Schwarz A, Enders C, Cameron S, Baumhoer D, Ramadori G, Lorf T, Gunawan B, Sander B. Etiologic influence on chromosomal aberrations in European hepatocellular carcinoma identified by CGH. Pathol Res Pract 2013; 209: 380-387 [PMID: 23706943 DOI: 10.1016/j.prp.2013.04.004]
162. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg 2015; 261: 513-520 [PMID: 25072437]